New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010
PDPs reduce investment risks and stretch limited budgets leading to 375 innovations targeting infectious diseases under development.
28 Jan 2021
The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. This is another powerful example of how public-private partnerships have established themselves as powerhouses for fighting global health threats. According to a new report launched today from a group of 12 product development partnerships (PDPs), over the last decade, such alliances have brought to market 66 new drugs, vaccines, diagnostics and other technologies for a number of diseases including tuberculosis, malaria,
The Good Men Project
Become a Premium Member
We have pioneered the largest worldwide conversation about what it means to be a good man in the 21st century.
Your support of our work is inspiring and invaluable.
If a Medicine Is Too Expensive, Should a Hospital Make Its Own?
When the price of an essential medicine rose to an unacceptable level, there was only one thing for pharmacist Marleen Kemper to do – start making it herself.
When Marleen Kemper was a child, she watched two of her primary-school classmates get ill. One had a brain tumour, and the other contracted an infection in his gut. Both of them died. Kemper was around ten at the time, and knew that she didn’t want to see another friend perish. She told her parents she wanted to do something that would prevent others dying. She wanted to be a doctor.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Biosimilar Therapeutic Peptides Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar therapeutic peptides market.
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S.
The global biosimilar therapeutic peptides market is expected to decline from $0.80 billion in 2019 to $0.77 billion in 2020 at a compound annual growth rate (CAGR) of -3.45%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chai
Rosalie Liccardo Pacula PhD is a Full Professor and the Elizabeth Garrett Chair in Health Policy, Economics & Law in the Sol Price School of Public Policy and the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. She also serves as Co-PI of the NIH P50 funded RAND/USC Opioid Policy Tools and Information Center of Excellence (OPTIC) and is the Co-Director of USC’s Institute on Addiction Sciences Policy Affinity Group. Prior to coming to USC, she spent 15 years as the Co-Director of RAND’s Drug Policy Research Center, which provided her the opportunity to educate and engage with policy makers at the state, federal and international level on policies related to alcohol, cannabis, opioids among others.
There is hardly any doubt that failing health systems result in poor health outcomes and hamper progress towards the attainment of the Sustainable Development Goals (SDGs) and Universal Health Coverage (UHC). In Africa, health systems are hobbled by leadership and governance challenges, extreme shortages of health workers, corruption in procurement systems for medical products and technologies, poor information systems, and health financing constraints. This brief discusses ways in which decision-makers can hurdle these challenges.
Attribution: Daniel Mwai & Theresa Ndavi, “What Ails Health Systems in Africa? An Economic Perspective,”
ORF Issue Brief No. 431, December 2020, Observer Research Foundation.
Introduction
Most African countries gained independence between the 1950s and 1960s. In order to build their economies, import substitution policies were encouraged as a conduit for economic growth and industrialisation. Advocates of import substitution argued that developing